| Original language | English (US) |
|---|---|
| Pages (from-to) | E114-E117 |
| Journal | American Journal of Hematology |
| Volume | 96 |
| Issue number | 4 |
| DOIs | |
| State | Published - Apr 1 2021 |
ASJC Scopus subject areas
- Hematology
Access to Document
Other files and links
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
Phase I study of escalating doses of carfilzomib with HyperCVAD in patients with newly diagnosed acute lymphoblastic leukemia. / Jonas, Brian; Fisch, Samantha C.; Rosenberg, Aaron S.; Hoeg, Rasmus; Tuscano, Joseph; Abedi, Mehrdad.
In: American Journal of Hematology, Vol. 96, No. 4, 01.04.2021, p. E114-E117.Research output: Contribution to journal › Letter › peer-review
}
TY - JOUR
T1 - Phase I study of escalating doses of carfilzomib with HyperCVAD in patients with newly diagnosed acute lymphoblastic leukemia
AU - Jonas, Brian
AU - Fisch, Samantha C.
AU - Rosenberg, Aaron S.
AU - Hoeg, Rasmus
AU - Tuscano, Joseph
AU - Abedi, Mehrdad
N1 - Funding Information: We thank the patients for participating in this study and Takeda for funding this study. We thank the University of California, Davis Comprehensive Cancer Center (UCDCCC) Office of Clinical Research for support in the conduct and analysis of the trial. The abstract form of preliminary data from this study was presented at ASH 2019: Abstract #3884. ACUTE LYMPHOBLASTIC LEUKEMIA: THERAPY, EXCLUDING TRANSPLANTATION. This study was supported by the UCDCCC Support Grant awarded by the National Cancer Institute (NCI P30CA093373). Funding Information: BA Jonas has served in a consulting/advisory role for AbbVie, Amgen, Celgene, Genentech, GlycoMimetics, Jazz, Takeda, Tolero, and Treadwell. He has received travel support from 47, AbbVie, Amgen, and Glycomimetics. He has received research funding to his institution from AbbVie, Accelerated Medical Diagnostics, AROG, Celgene, Daiichi Sankyo, F. Hoffmann‐La Roche, Forma, Genentech/Roche, GlycoMimetics, Hanmi, Incyte, Jazz, LP Therapeutics, Pfizer, Pharmacyclics, and Sigma Tau. SC Fisch reports no conflicts of interest. AS Rosenberg has received research funding from Amgen. He has participated in Speakers Bureaus for Jannsen and Millenium‐Takeda. He has served in a consulting/advisory role for Seattle Genetics and Karyopharm. RT Hoeg reports no conflicts of interest. JM Tuscano has received research funding from Celgene, Novartis, Achrotech, Pharmacyclics, Genentech and Takada. He has received honoraria from Celgene, Amgen and Seattle Genetics. M Abedi has participated in Speakers Bureaus for AbbVie, Celgene, BMS and Gilead. Funding Information: We thank the patients for participating in this study and Takeda for funding this study. We thank the University of California, Davis Comprehensive Cancer Center (UCDCCC) Office of Clinical Research for support in the conduct and analysis of the trial. The abstract form of preliminary data from this study was presented at ASH 2019: Abstract #3884. ACUTE LYMPHOBLASTIC LEUKEMIA: THERAPY, EXCLUDING TRANSPLANTATION. This study was supported by the UCDCCC Support Grant awarded by the National Cancer Institute (NCI P30CA093373). Copyright: Copyright 2021 Elsevier B.V., All rights reserved.
PY - 2021/4/1
Y1 - 2021/4/1
UR - http://www.scopus.com/inward/record.url?scp=85101787032&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85101787032&partnerID=8YFLogxK
U2 - 10.1002/ajh.26105
DO - 10.1002/ajh.26105
M3 - Letter
C2 - 33476436
AN - SCOPUS:85101787032
VL - 96
SP - E114-E117
JO - American Journal of Hematology
JF - American Journal of Hematology
SN - 0361-8609
IS - 4
ER -